Company to host conference call and webcast on
The conference call will be available on Acadia’s website, www.acadia.com under the investors section and will be archived there until
About
Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapies for hallucinations and delusions associated with Parkinson’s disease psychosis and for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Prader-Willi syndrome, Alzheimer’s disease psychosis and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia.com and follow us on LinkedIn and Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231019859462/en/
Media Contact:
Deb Kazenelson
(818) 395-3043
[email protected]
Investor Contact:
(858) 261-2872
[email protected]
(858) 261-2950
[email protected]
Source: